Immune Checkpoints and Innovative Therapies in Glioblastoma
Targeting the Immune Checkpoint molecules (ICs; CTLA-4, PD-1, PD-L1/2, and others) which provide inhibitory signals to T cells, dramatically improves survival in hard-to-treat tumors. The establishment of an immunosuppressive environment prevents endogenous immune response in glioblastoma; therefore...
Main Authors: | Massimo Romani, Maria Pia Pistillo, Roberta Carosio, Anna Morabito, Barbara Banelli |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00464/full |
Similar Items
-
Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01) -
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01) -
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01) -
Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01)